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Abstract 
Introduction: 
Red blood cell transfusion has greatly reduced the mortality and morbidity in multiply 
transfused thalassemia patients. However, this can result in red blood cell isoimmunization 
with alloantibodies which can lead to serious complications such as acute and delayed 
hemolytic transfusion reactions. 
Objectives: 
To assess the frequency and types of alloantibodies in transfusion-dependent thalassemia 
patients in the middle and southern regions of the West Bank. Furthermore, to assess the 
association between alloantibody development and gender, age of first transfusion, blood 
type, splenectomy, frequency of transfusion. 
Methods: 
This cross-sectional study was performed between February and June, 2017 at three 
Thalassemia Centers in the southern and middle districts of the West Bank. A total of 101 
transfusion-dependent thalassemia patients from these centers were included. Clinical and 
transfusion records were examined for age of patients, age at first transfusion therapy, total 
number of blood units transfused, and the status of spleen. Alloantibody screening and 
identification was also performed by using the gel card method (Diamed ID, Switzerland). 
 
Results: 
Eleven out of one hundred and one participants (10.9%) had alloantibodies. Ten of them 
(90.9%) were diagnosed with β-thalassemia major, and one (9.1%) was diagnosed with β-
thalassemia intermedia. The majority of alloimmunized patients were females (8; 72.7%). 
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Eight patients (72.7%) were splenectomized. Seven patients (63.6%) had single 
alloantibody, while four (36.4%) developed multiple alloantibodies. 
Six types of alloantibodies were identified, three (50%) were against antigens from the Rh 
system (anti-E, anti-C and anti-D), two (33.3%) were against antigens from the Kell 
system (anti-K and anti-Kp
a
) and one (16.7%) was against an antigen from the Kidd-
system (anti-Jk
a
). 
Conclusions: 
This data showed quite high alloimmunization rate among transfusion-dependent 
thalassemia patients in the middle and southern regions of the West Bank. The most 
frequently detected alloantibodies were against the Rh and Kell antigens. 
In order to reduce the alloimmunization in these patients, a policy to perform extended red 
cell phenotyping of the patients and issuing antigen-matched blood should be adopted. 
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Chapter One 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ
Introduction 
 
Complications due to erythrocyte alloimmunization make transfusion therapy problematic 
in transfusion-dependent patients, including thalassemia patients. 
The Food and Drugs Administration (FDA) identifies non-ABO antibodies as the second 
leading cause of mortality associated with blood transfusion in the period from 2005 to 
2013 in the United State of America (USA) (FDA, 2012). Serious Hazards of Transfusion 
"SHOT" indicates that alloimmunization and hemolytic transfusion reactions are the 
second most common pathologic complication from transfusion in the United Kingdom 
(UK) (SHOT, 2015).  
In developing countries, regular blood transfusion remains the main treatment for 
thalassemia, so the mortality associated with transfusion due to alloimmunization in these 
countries could be higher than that in the UK or USA, though there are no data available 
about mortality associated with transfusion due to alloimmunization. In these countries, 
complete phenotype screening for recipient patients and transfused red blood cell units are 
not routinely done. Only ABO and Rh-D typing is routinely done before transfusion with 
the indirect anti-globulin test -IAT. The lack of knowledge of other blood group system 
screening methods could lead to an increase in the frequency of alloimmunization in such 
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countries. However, no data are available about the frequency of erythrocyte 
alloimmunization in transfusion-dependent thalassemia patients in the State of Palestine. 
Following transfusion, pregnancies/delivery or transplantations, exposure to foreign RBC 
antigens may occur, which could lead to an immune response and antibody production 
against foreign RBC antigens. This immune response is called alloimmunization while the 
related antibodies are called alloantibodies. 
In blood transfusion, the first exposure to foreign antigens stimulates the immune system 
which produces corresponding antibodies against this foreign antigen. This first immune 
response does not lead to hematological complications, but with time, the concentration of 
these alloantibodies is decreased and will be undetected by immuno-hematological tests. 
The second exposure to the same antigen results in a secondary immune response and leads 
to the production of high amounts of gamma immunoglobulins (IgG) which sensitize the 
transfused red cells. This sensitization leads to a delayed hemolytic transfusion reaction. 
This hemolysis leads to an increase in the medical complication of anemia for the 
recipient. Moreover, the presence of alloantibodies makes it difficult to provide compatible 
red blood cell units for transfusion. 
Thalassemia is one of the most common hemoglobinopathies worldwide. About 60,000 
children are annually born affected by β-thalassemia (TIF, 2007). The first description of 
thalassemia was done in 1925 in Detroit by Thomas Cooley. 
Thalassemia is a diverse group of congenital hematological diseases which occurs as a 
result of mutation or mutations in one or more globin genes. These mutations lead to the 
decrease or absence of the synthesis of corresponding globin chains. The most common 
types are α and β thalassemia which are considered the result of mutations in α or β genes 
which affect hemoglobin A (the major adult form of hemoglobin). 
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In normal hemoglobin A, the α chain to β chain ratio is one to one but in β thalassemia, the 
mutations in the β gene lead to a reduction or even absence in the amount of β globin chain 
which leads to an excess in the amount of α chain. Excess α chains bind to erythrocyte 
membranes which causes a decrease in erythrocyte deformability and erythrocyte 
membrane damage. These excess α chains are the major source of anemia in β thalassemia. 
In the bone marrow, macrophages destroy precipitate-filled erythrocytes which lead to 
ineffective erythropoiesis. Moreover, circulating erythrocytes with excess precipitate α 
chains are removed by the spleen in the extravascular hemolysis mechanism (Hoffbrand, 
Higgs, Keeling, & Mehta, 2016; McKenzie, Williams, & Landis-Piwowar, 2015). 
Beta thalassemia is classified depending on its severity. This classification includes: major 
thalassemia, which is defined as a type of thalassemia with severe clinical phenotype due 
to homozygote mutation in the beta-globin gene; intermedia thalassemia, which is the type 
of thalassemia with intermediate clinical phenotype because the beta gene still can encode 
some beta chains; and minor thalassemia, which is the type of thalassemia that is also 
called thalassemia trait because one normal beta globin gene is present and, as a result, 
mild clinical phenotype is presented (Jha R, 2014).  
Patients with major β thalassemia need medical attention and require regular blood 
transfusion within the first two years of life. The goal of regular blood transfusion is to 
maintain the hemoglobin level between 9.5 and 10.5 g/dl which allows for normal 
developmental growth (Jha R, 2014). Lifelong blood transfusions are needed for major β 
thalassemia patients which leads to an increase in the side effects of blood transfusions 
such as iron overload, transfusion-transmitted infections and delayed hemolytic transfusion 
reactions due to the presence of alloantibodies. This study focuses on alloimmunization in 
transfusion-dependent thalassemia patients in the West Bank.  
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Depending on recently updated data from Thalassemia Patients Friends Palestinian Society 
(TPFS), in the West Bank, there are 566 thalassemia patients; 500 (88%) of them are 
transfusion-dependent while the other 66 cases were treated by bone marrow 
transplantation outside the State of Palestine. Red blood cell transfusion remains the main 
treatment available for thalassemia patients in the State of Palestine (TPFS, 2017). 
  
1.1.Problem Statement 
Alloantibodies against non-ABO antigens are identified as the second cause of mortality 
associated with blood transfusion by FAD and SHOT in the USA and the UK respectively 
(FDA, 2012; SHOT, 2015). 
These antibodies are formed after exposure to foreign erythrocyte antigens which stimulate 
the immune system to produce antibodies against these antigens. These alloantibodies can 
be detected by pre-transfusion testing. The reaction due to the presence of alloantibodies 
could occur in 2.6% of transfusions. 
Alloantibody formation is common in chronic transfusion-dependent patients as well as in 
hematological malignancies and hematological diseases such as thalassemia and sickle cell 
diseases. In the West Bank, thalassemia is the most common type of hemoglobinopathy. 
Recommendations for compatibility screening of phenotypes for blood group systems 
other than ABO and Rh-D could reduce the frequency of alloimmunization for these 
patients and avoid any complications. This would also allow the patients to get the utmost 
benefits from transfused units. 
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1.2. Study Justification 
This research study aims to screen the blood of thalassemia transfusion–dependent patients 
for circulating antibodies in order to identify them. The study also aims to develop 
recommendations for health authorities to start screening blood units for the presence of 
these particular antigens in order to give patients fully matched blood which helps them 
avoid any complications. This will allow them to get the utmost benefit of the transfused 
units. 
 
1.3. Objective 
1.3.1. Main objective: 
The main objective of our research is to determine the frequency and identification of 
alloantibodies among transfusion-dependent thalassemia patients in the West Bank. 
1.3.2. Specific objectives: 
The first specific objective of our research is to identify the frequency of each alloantibody 
in transfusion-dependent thalassemia patients in the West Bank. 
The second specific objective of our research is to assess the association between 
development alloantibody and factors such as gender, age at the first transfusion, ABO and 
Rh blood group, splenectomy, and frequency of transfusion. 
1.4. Hypotheses 
Tow hypotheses were consider. First, that there is no alloimmunization among transfusion-
dependent thalassemia patients in the West Bank. Second, there is no significant 
association between alloimmunization and Splenectomy, gender, frequency of transfusion, 
number of transfused units, blood group and age. 
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Chapter Two 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
2. Literatures Review 
 
2.1.Introduction  
From the beginning of history, humans have been interested in blood: the ancient 
Egyptians bathed in blood, blood was drunk by aristocrats, and authors and artists have 
used blood as themes. Nowadays, in modern medicine, blood transfusions are a 
cornerstone for the treatment of many diseases and medical cases and transfusion medicine 
is rapidly developing (Harmening, 2012). However, the risks and side effects of blood 
transfusion have also developed beside the wide use of blood and blood products in 
medicine, and therefore should be minimized. One of these risks is the presence of 
alloantibodies against foreign red cell antigens and the delayed hemolytic transfusion 
reaction which is associated with these types of antibodies. Alloantibodies minimize the 
availability of compatible units for patients, which could lead to complicating the patient's 
condition. 
2.2.History of Transfusion 
The first blood transfusion process in history was done in 1492 when blood was transferred 
from three volunteer donors to Pope Innocent VII, who was bleeding. The four people 
involved died in the blood transfusion process. In 1818, James Blundell and Thomas 
published the first report of a blood transfusion by syringe. Clotting formation hold-back 
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lead to failing these historical blood transfusion processes, but this was solved by Braxton 
Hicks, who recommended in 1869 using sodium phosphate as a non-toxic anticoagulant. In 
1914, sodium citrate was reported by Hustin as an anticoagulant for transfusion, and in 
1916, citrate dextrose solution was identified in blood preservation by Rous and Turner. In 
1943, acidic citrate dextrose (ACD) as a blood preservative solution was identified by 
Loutit and Mollison. In 1957, Gibson identified citrate phosphate dextrose (CPD) for blood 
preservation. Citrate phosphate dextrose consists of citrate and dextrose; citrate plays a role 
in calcium chelation to prevent clot formation and dextrose plays a role in cellular energy 
by providing adenosine triphosphate ATP. In 1979, Ernest Beutler and Carol West 
suggested that the addition of adenine and increasing the amount of glucose to CPD 
provides more stability for blood units by persevering which is called citrate phosphate 
adenine (CPDA). The main goal of blood preservation is to provide functional and viable 
blood components for patients, and according to FDA identified criteria, free hemoglobin 
should be less than 1% and the average 24-hour post-transfusion erythrocyte survival 
should be more than 75%. Under these criteria, blood unit stability depend on the type of 
preservative, as CPD is stable for 21 days whereas CPDA-1 is stable for 35 days at 1-6
ο
C 
(Beutler & West, 1979; Blundell, 1818; Harmening, 2012). 
In 1869, Adolf Criete reported that after mixing red blood cells from one species with 
serum from another species, the red blood cells form an agglutination (Harmening, 2012). 
The difference in red blood cell agglutination was described by Austrian pathologist Karl 
Landsteiner in 1901 and led to the ABO blood group system and its serious reactions that 
could occur as a result of an incompatible transfusion. In 1911, Reuben Ottenberg 
introduced the ABO blood grouping test to select compatible donors, which led to a 
reduction in fatalities from blood transfusion in the early days after transfusion and 
recommended to perform cross-matching beside ABO blood grouping as routine pre-
   8 
 
transfusion testing. However, the Ottenberg cross-matching technique needed 10-15 ml of 
blood and 2 hours incubation, so later on, Ross and Lee improved the cross-matching 
technique by reducing the blood volume and incubation time to less than 15 minutes (Lee, 
1917; Rous & Turner, 1915). The first non-ABO antibody was identified in 1921 by Under 
(Unger, 1921). These irregular antibodies were detected well after 30 minutes of 
incubation at 37
ο
C, this suggestion was done by Levine and Diamond who suggested that 
bovine albumin enhances aggregation. In 1940, an antibody was reported by Landsteiner 
and Wiener from pigs and rabbits when they were transfused with Rhesus macaque 
monkey RBCs. This antibody was agglutinated 85% of human RBCs and was termed Rh 
for Rhesus monkey (Harmening, 2012). 
In 1945, Coombs introduced a new test to detect weak and incomplete agglutinins called 
the indirect antiglobulin test. The indirect antiglobulin test added a new dimension to the 
safety of blood transfusion and lead to a rapid increase in the identification of 
alloantibodies that caused transfusion reactions (R. R. Coombs, Mourant, & Race, 1945). 
To further increase transfusion safety, sensitive cross-matching protocols were developed, 
including direct antiglobulin tests and auto-controls. Enzyme-treated red blood cells and 
additives such as bovine albumin, low ionic strength media and polyethylene-glycol (PEG) 
were used to enhance agglutination and to further shorten incubation times. Using these 
sensitive techniques, many new blood group systems were discovered. This revolution in 
blood transfusion and transfusion medicine in the 20
th
 century led to massive blood use 
which caused circulatory overload in many patients. This problem was solved by blood 
component therapy, where each blood component is available as a concentrated form such 
as packed red blood cells, concentrated platelets and cryoprecipitate (rich in anti-
hemophilic factors). 
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2.3.Blood Group Systems 
In human erythrocytes, 322 different antigens in 36 different systems have been identified 
by The International Society of Blood Transfusion (ISBT, 2016). These systems include 
the ABO system which includes A antigen and B antigen, the Rh system which includes D, 
C, c, E and e antigens, … etc. (Appendices 1 and 2).  
The most recently discovered system is the Augustine system, which includes four 
antigens. The Rh system is the biggest blood group system which includes 55 antigens, 
followed by the MNS system with 49 antigens (ISBT, 2018).  
Erythrocyte antigens have different structures that lead to a diversity in their functions. 
These antigens reside on erythroid membrane glycoproteins or glycolipids, though they are 
not erythroid-specific antigens and could be present on the surface of other cells.  
Erythrocyte antigens have a biological function; a transporter function with Colton 
antigens (CO) playing a role as a water channel, Kidd antigens (JK) playing a role as a urea 
transporter, and Diego antigens (DI) playing a role as an anion exchanger. Erythrocyte 
antigens function as receptors, such as Duffy antigens (FY) and Knobs antigens (KN), and 
have adhesion functions such as Indian antigens (IN) and Landsteiner-Wiener antigens 
(LW). Finally, erythrocyte antigens have enzymatic functions such as Kell antigens (KEL) 
and YT antigens Zn-Metalloproteinase and Acetylcholinesterase respectively. Other 
antigen systems such as the Scianna system and Raph system have unknown functions. 
(Cartron & Colin, 2001)  
Genetically, blood group antigens are encoded by the same gene classified in the same 
blood group system where each blood group system could consist of one or more antigens. 
Most blood group polymorphisms are the result of single nucleotide polymorphisms 
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(SNPs) encoding amino acid substitutions in an extracellular domain of an RBC surface 
protein (Storry & Olsson, 2004). 
 
2.4.Pretransfusion Testing 
The ABO and Rh blood grouping test is the key test for blood transfusion and major cross-
matching by mixing donor RBC suspensions with the patient's serum to ensure there are no 
antibodies present in their plasma against the RBC antigens of the donor.  
However, the major cross match test cannot detect alloantibodies in all titrations because 
alloantibodies after a certain period of time are undetectable by in vitro testing. 
Phenotyping for patients and donors could minimize the formation of these alloantibodies. 
The formation of alloantibodies is variable between individuals, so the human population 
is classified as non-responder, responder and hyper responder depending on the 
susceptibility to alloantibody formation after exposure to foreign antigens (Gehrie & 
Tormey, 2014). 
2.4.1. Antiglobulin Test: 
The antiglobulin test, also known as the Coombs test, depends on the antihuman globulin 
AHG obtained from immunized non-human species binding to human globulins such as 
IgG and complements in free form in serum or binding form to erythrocyte antigens. The 
first description of this test was done by Coombs to detect weak or non-agglutinating Rh-
antibodies in 1945 (R. R. Coombs et al., 1945).  
The anti-human globulin test detects incomplete or non-agglutinating antibodies such as 
IgG1 and IgG3 because they are monomers that are too small and cannot directly 
agglutinate sensitized RBCs. Therefore, adding antihuman globulin to RBCs, which are 
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sensitized by incomplete antibodies, leads to the hemagglutination of these sensitized 
RBCs, helping to observe the undetectable formation of the antibody-antigen complex.  
In 1946, Coombs, and co-workers suggested that the antihuman globulin test could be used 
to detect the in vivo sensitization of the RBCs of newborns which leads to hemolytic 
disease (R. Coombs, Mourant, & Race, 1946). The anti-human globulin test is classified 
into two tests, the direct and indirect antihuman globulin tests. This classification depends 
on the sensitization environment, with the direct antihuman globulin test detecting 
sensitized RBCs in vivo while the indirect antihuman globulin test detects sensitized RBCs 
in vitro (Harmening, 2012).  
Various technical modifications have increased the sensitivity of the detection of antibody-
coated RBCs, such as using more specific AHG as mono-specific AHG against IgG or 
complement C3. Moreover, one of these modification techniques is enzyme elution of the 
antibodies from the coated RBCs (Alwar, Devi, Sitalakshmi, & Karuna, 2012).  
In 1990, the first description of gel techniques using antibody coated RBCs was done by 
Lappierre (Lapierre et al., 1990). This new technique is based on the Sephadex gel matrix 
which acts as a sieve, where agglutinated RBCs are too large to pass through and are 
trapped in the gel matrix. The negative reaction is observed as a clear pellet of cells that 
have settled at the bottom of the microtube. But this new technique still has a limitation 
with 60.46% specificity and 83.01% sensitivity. False positive results occur due to high 
Erythrocyte Sedimentation Rate ESR, macrocytosis, and marked leukocytosis, so positivity 
by the Sephadex gel matrix  method needs to be correlated with the clinical presentation of 
the patient and other laboratory findings and a positive result needs to be confirmed by 
monospecific antisera (Alwar et al., 2012). 
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2.4.2. Crossmatch: 
One of the application tests of the indirect Coombs test is a crossmatch test. This test 
detects the patient's antibodies sensitizing donor erythrocyte antigens in vitro to suspect 
this process in vivo. A negative or compatible crossmatch test (no sensitized donor RBCs 
by recipient antibodies) indicates safe blood transfusion for the patient. 
 
2.4.3. Antibody Identification: 
Another application test of the indirect Coombs test is an antibody identification test. This 
test is done after detection antibody or antibodies in the patient's serum. By using a 
commercial panel of cells with known antigens, the antibody or antibodies present in the 
patient's serum can be identified. About 30-40% of alloantibodies are undetectable months 
or even years after their first identification, (Calabro et al., 2016) and there are many 
techniques available to enhance agglutination reactions such as the low ionic strength 
saline (LISS) technique, the albumin and papain technique and the polyethylene glycol 
(PEG) technique. The polyethylene glycol antiglobulin technique was reported as the most 
sensitive technique (Pineda, Vamvakas, Gorden, Winters, & Moore, 1999). 
 
2.5. Risks associated with Transfusion 
Blood transfusion is a life-saving procedure, though it involves risks. Some of these risks 
could be prevented by testing, while others cannot but can be managed under medical 
observation. Transfusion reactions are classified by the interval time between the 
transfusion and reaction occurring in two groups: acute transfusion reactions (ATR) and 
delayed transfusion reactions (DTR). 
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2.5.1. Acute Transfusion Reactions: 
Acute transfusion reactions are defined as any transfusion reaction occurring with signs 
and symptoms present within 24 hours post-transfusion.  
One of the acute transfusion reactions is the acute hemolytic transfusion reaction which is a 
hemolytic complication post-transfusion within 24 hours. These reactions are classified 
into immune and non-immune origin. For immune origin, a small amount of incompatible 
blood can cause rapid hemolysis. The severity of symptoms is related to the amount and 
rate of incompatible blood transfused in which the most severe reaction is associated with 
ABO incompatibility. ABO incompatible transfusions are estimated to occur in one in 
every 38,000 - 70,000 RBC transfusions.  
Acute hemolytic transfusion reaction symptoms include back and flank pain, 
hemoglobinuria, hemoglobinemia, hypotension, renal failure and diffuse intravascular 
coagulopathy. Non-immune origin acute hemolytic transfusion reactions include 
transfusion associated-sepsis. Moreover, the febrile non-hemolytic transfusion reaction is 
an acute transfusion reaction with a high frequency of 0.12-0.5% of transfused RBC units 
(Harmening, 2012; Kaushansky, 2016). 
2.5.2. Delayed Transfusion Reactions: 
Any transfusion reaction occurring post-transfusion with signs and symptoms that appear 
after 24 hours is defined as a delayed transfusion reaction. One delayed transfusion 
reaction is the delayed hemolytic transfusion reaction (DHTR). This type of transfusion 
reaction occurs as a result of the presence of alloantibodies, but in undetectable 
concentrations, so the cross-match result appears compatible. This occurs as a result of a 
special characteristic of alloantibodies, as 30-40% are undetectable after months to years of 
their first identification. This type of transfusion reaction occurs in 0.2-2.6% of transfused 
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patients and is rare in infants younger than 4 months but common in chronically transfused 
patients. A first transfusion or pregnancy can lead to immunization of the patient, while a 
second transfusion or pregnancy with re-exposure to a blood group antigen can lead to a 
secondary immune response with the rapid production of IgG antibodies. These antibodies 
sensitize RBCs and lead to extravascular hemolysis, which appears as a decrease in 
hematocrit and hemoglobin levels, which could be noted days to weeks after transfusion. 
This is also associated with unexplained fever. The delayed hemolytic transfusion reaction 
is mostly extravascular hemolysis but some classes of IgG could bind complement and 
cause intravascular hemolysis. Anti-Kidd causes rapid, severe and extravascular hemolysis 
(Harmening, 2012; Kaushansky, 2016). A significant cause of DHTR is the presence of 
undetectable clinically significant antibodies, due to low titer which can lead to these 
antibodies being too weak to be detected at the time of pre-transfusion testing (Pineda et 
al., 1999). 
Iron overload is also a blood transfusion complication that appears clear especially in 
chronically transfusion dependent patients because each mL of packed red blood cells 
contains 1mg of iron, which means each packed cell unit contains 200-250 mg of iron. 
This large amount of iron accumulates in the tissues of organs including the pancreas, 
thyroid gland, and heart leading to their failure (Kaushansky, 2016). 
 
2.6. Alloimmunization 
Alloantibodies act against foreign erythrocyte antigens after being exposed to them. This 
exposure could occur after blood transfusion, solid organ transplantation or pregnancy 
through delivery. The immune response mechanism to the formation of alloantibodies is 
called alloimmunization. Alloimmunization could lead to mortality or morbidity by 
causing hemolytic transfusion reactions. This hemolysis could cause renal failure. Patients 
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with alloantibody against high frequent antigens or with multiple alloantibodies could have 
complications related to anemia due to late in providing of compatible units for 
transfusion. For certain diseases, this delay could be lethal. 
2.6.1. Clinical Predictors of Alloimmunization: 
Many different factors influence the possibility of transfusion recipients forming 
erythrocyte alloantibodies, including recipient or donor/product related factors.  
Alloimmunization depends on individual susceptibility to developing alloantibodies. 
Individuals with a high susceptibility to alloimmunization are dubbed alloantibody 
responders. Identifying the clinical conditions that predispose to alloimmunization is 
important to influence the management of a patient and lead to better understanding the 
etiology of transfusion reactions associated with alloimmunization. Bauer et al. identified 
solid malignancy, diabetes mellitus, and female gender as risk factors for alloimmunization 
against erythrocyte antigens but symptomatic atherosclerosis and lympho-proliferative 
disorders were identified as a protector against alloimmunization (Bauer, Wiersum-
Osselton, Schipperus, Vandenbroucke, & Briet, 2007). Schonewille et al. reported that the 
possibility of the formation of alloantibodies in patients who formed a single alloantibody 
could be increased by 29-fold to form additional alloantibodies compared to those who had 
not already been alloimmunized (Schonewille, van de Watering, & Brand, 2006). One of 
the most important factors related to recipient impact alloimmunization is the genetic 
factor which is responsible for variability in Human Leukocyte Antigen (HLA). Human 
leukocyte antigens variability affects the ability to process and present particular peptides 
derived from erythrocyte antigens by class I and class II Major Histocompatibility 
Complex (MHC), where some types of HLA may be associated with responder phenotypes 
more than others (Schonewille et al., 2014). 
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Moreover, there are factors that impact alloimmunization that are not related to recipient 
patients. These factors include the non-RBC contents of transfused RBC units such as 
leukocytes and their remnants, platelets and their remnants, and soluble factors including 
cytokines. These remnants are variable among transfusion centres as a result of 
methodologies of blood collection and processing, lengths of holding time prior to 
processing, leukoreduction filter techniques and centrifugation speeds. These variables 
impact alloimmunization through impact recipient immune response by the ability of cells 
and cell remnants to induce a pro-inflammatory response driving T-cell proliferation 
(Danesh et al., 2014). During the storage of blood, microRNAs (miRNA) are produced in 
varying quantities (Kannan & Atreya, 2010). Some studies suggest that miRNAs are 
involved in regulating the immune response by influencing T-helper cell differentiation, 
which could lead to miRNAs having a potential role in alloimmunization (Baumjohann & 
Ansel, 2013), for which old RBC units have a higher possibility to induce 
alloimmunization. Antigen specificity is different for different antigens, so antigen type 
impacts the alloimmunization response due to differences in antigen structures. Therefore, 
some erythrocyte antigens are more immunogenic than others. 
2.6.2. Mechanism of Erythrocyte Alloimmunization: 
Erythrocyte alloimmunization is one of the immune responses against foreign antigens, 
alloantigens in this mechanism are erythrocyte foreign antigens. After erythrocytes are 
phagocytosed by macrophages, monocytes or dendritic cells, the proteins carrying the 
alloantigenic epitopes are processed. When antigenic epitopes are processed, these epitopes 
bind to the groove of HLA class II molecules and are presented to the T cell receptor of 
CD4 positive T cells. CD4 positive T cells then activate B cells, which are also able to 
recognize the antigenic epitopes, which activate B cells subsequently and produce 
antibodies against the corresponding epitopes. In contrast with HLA class I and class II, the 
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antigen-binding groove of MHC class II molecules is open at both ends while the 
corresponding groove on class I molecules is closed at each end. The antigens presented by 
MHC class II molecules are longer and consist of 15-24 amino acid residues while HLA 
class I molecules encompass 8–10 amino acids (Kormoczi & Mayr, 2014). 
 
2.7. Thalassemia and Chronic Blood Transfusion 
Thalassemia is defined as the reduction in the synthesis rate of one or more globin chains 
leading to imbalanced globin chain synthesis which leads to defective hemoglobin 
production. This imbalance in globin chain synthesis occurs as a result of mutations in 
globin genes which leads to a reduction in the rate of synthesis of the corresponding globin 
chains of hemoglobin. Therefore, thalassemia is classified depending on the globin gene 
which is affected by mutations and its corresponding globin chain.  
The first description of thalassemia was offered in 1925 in Detroit by Thomas Cooley. 
Nowadays, thalassemia is identified as the most common hemoglobinopathy worldwide, 
with about 60,000 children born annually being affected with β-thalassemia (TIF, 2007) 
and immigrations to European countries and other countries make thalassemia as 
worldwide disorders. 
2.7.1. Normal Hemoglobin: 
Hemoglobin is a specialized intracellular erythrocyte protein with a molecular weight of 
66,700 Daltons. This protein is responsible for transferring oxygen from the lungs to the 
tissues of the body. Each gram of hemoglobin can carry 1.34 ml of oxygen. About 33% of 
the volume of an erythrocyte and about 90% of a cell's dry weight are occupied by 
hemoglobin, with each erythrocyte containing 28-34 pg of hemoglobin. Anemia occurs as 
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a result of a decreased amount of hemoglobin in erythrocytes or a reduction in the 
erythrocyte count. 
 Hemoglobin synthesis begins in the pronormoblast stage but with a small amount. Most 
hemoglobin synthesis occurs in the development of normoblasts at the polychromatophilic 
normoblast stage. About 75-80% of hemoglobin is synthesized before extrusion of the 
nucleus and 20-25% is synthesized in reticulocytes by using residual RNA and 
mitochondria (McKenzie et al., 2015). 
In general, the hemoglobin molecule is a tetramer consisting of four globular protein 
subunits, with each subunit having a hem group and globin chain, (Figure 2.1) and (Figure 
2.2). The hem group consists of a tetrapyrrole ring, with ferrous iron located at its centre, 
(figure 2.3). 
Globin chains are classified into two groups; alpha-like chains and non-alpha chains. 
Alpha-like chains include alpha (α) and zeta (δ) chains. Non-alpha chains include beta (β), 
delta (δ), epsilon (ε) and gamma (γ) chains.  
Each hemoglobin molecule consists of two identical alpha-like chains and two identical 
non-alpha chains. This variation in globin chains in hemoglobin molecules leads to the 
formation of different types of hemoglobin. Some of these types are present only in certain 
periods of human level of development such as hemoglobin Gower I (δ2ε2), Gower II (α2ε2) 
and Portland (δ2γ2), present only in embryonic blood and absent in foetal and adult blood. 
Other types of hemoglobin are present in different levels of human development but with 
different 
percentages of total hemoglobin such as hemoglobin F (α2γ2), which is the predominant 
form of hemoglobin in the foetus and newborns. Moreover there is a small proportion of 
hemoglobin A (α2β2) in foetal blood, though in adults hemoglobin A1 is the predominant 
form with a small proportion of hemoglobin F and hemoglobin A2 (α2δ2).  
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The main function of hemoglobin is to transport oxygen from the lungs to tissues, but these 
different types of hemoglobin have different oxygen affinity (McKenzie et al., 2015). 
 
 
 
Figure 2.1: General Structure of Hemoglobin A1. 
 
 
 
Figure 2.2: The Structure of hemoglobin: a: Primary structure: sequence of amino acids; b: 
Secondary structure: coiled α-helix and β-pleated sheet; c: Tertiary structure: folding of the 
molecule into a three-dimensional form; d: Quaternary structure: combination of four 
polypeptide subunits. 
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Figure 2.3: Structure of hem group 
 
2.7.2. Thalassemia Pathophysiology: 
Thalassemia is not a single disease but a group of diseases, each resulting from inherited 
abnormalities of globin production leading to a reduction in the rate of synthesis of one or 
more globin chains. The anemia present in thalassemia patients is a physiological result of 
imbalanced globin chain production which leads to ineffective erythropoiesis and 
hemolysis. In β thalassemia, there are two main forms; one is major β thalassemia as a 
result of the absence or decrease of β chain production and its formula as β0-thalassemia 
and β+ -thalassemia, while the other form is intermediate or minor β thalassemia which has 
a partial deficiency of β chain production. β-thalassemia is distributed widely in 
Mediterranean populations, the Middle East, parts of India and Pakistan, and throughout 
Southeast Asia. However, nowadays, immigrations to European countries make 
thalassemia as worldwide disorders. In normal hemoglobin A1, the α chain to β chain ratio 
is one to one but in β thalassemia, the mutation in the β gene leads to a reduced amount of 
β globin chains or a total absence which leads to an excess in α chains. In major β 
thalassemia, this ratio is reduced to less than 0.25 (McKenzie, 2015, Kaushansky, 2016).  
Excess α chains cannot form tetramers, so this excess of α chains binds to the erythrocyte 
membrane and leads to a decrease in erythrocyte deformability and membrane damage due 
to the presence of reactive oxygen species which are generated by the presence of free iron 
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and hemichromes in accumulated α chains. These excess α chains are the major source of 
anemia in β thalassemia patients: the oxidation of membrane band 3 leads to the clustering 
of proteins which create new antigens on the cell surface that bind to IgG and complement, 
leading to the destruction of IgG-complement sensitized erythrocytes in the bone marrow 
by binding macrophages by Fc receptors which lead to phagocytosis and the destruction of 
precipitate-filled erythrocytes which results in ineffective erythropoiesis and a large degree 
of hemolysis (McKenzie, 2015, Kaushansky, 2016). 
Excess precipitation of α chains also leads to the activation of the apoptotic mechanism 
which causes ineffective erythropoiesis. Furthermore, circulate erythrocytes with excess 
precipitate α chains are removed by the spleen in the extravascular hemolysis mechanism. 
This dramatic reduction in β globin leads to a dramatic reduction in hemoglobin A 
production and leads to an increase in the production of non-β chain containing 
hemoglobin such as hemoglobin F and hemoglobin A2. However, hemoglobin F has higher 
oxygen affinity than hemoglobin A1 which leads to exacerbating the compromised oxygen 
delivery to tissues and compensates stimulation erythropoiesis present as erythroid 
hyperplasia which causes bone marrow expansion and thinning of calcified bone. In 
addition, increased erythropoiesis activity leads to an increase in iron absorption in the gut 
which leads to an increase in iron toxicity. Ineffective erythropoiesis in the bone marrow is 
accompanied by extramedullary hemopoiesis in the liver and spleen which cause 
hepatosplenomegaly (McKenzie et al., 2015). 
At the molecular level, β thalassemia is extremely heterogeneous because there are more 
than 200 different mutations associated with its phenotype including deletions of the β 
globin gene and non-deletion mutations such as mutations that affect the transcription, 
processing or translation of β-globin messenger (Kaushansky, 2016). 
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2.8. Treatment of Thalassemia 
To reduce the side effects of anemia associated with thalassemia and maintain normal 
developmental and growth patterns is the main goal of thalassemia treatment. Regular 
transfusion is the main treatment for thalassemia major patients, but nowadays, thalassemia 
patients can be treated by stem cell transplantation if a compatible donor is available. 
Moreover, there are certain novel studies that have employed gene therapy in thalassemia 
treatment (Kaushansky, 2016). 
2.8.1. Chronic Blood Transfusion: 
Patients with thalassemia major need a regular blood transfusion to reduce the side effects 
of anemia and allow normal developmental and growth patterns by maintaining 
hemoglobin levels between 9 and 10.5 g/dl (Jha R, 2014). However, these lifelong 
transfusions lead to transfusion-associated side effects. These transfusion-associated side 
effects such as the large dose of iron received by chronic transfusion lead to tissue damage 
as a result of iron overload, so chronic transfusion is performed with iron chelation agents 
such as deferoxamine to decrease the deposition of iron in the tissues. Moreover, these 
chronic blood transfusions increase the probability of exposure to foreign erythrocyte 
antigens which stimulate the immune system to form alloantibodies. These alloantibodies 
reduce the availability of compatible blood units for thalassemia patients. Phenotype 
screening and compatibility between thalassemia patients and transfused units could reduce 
the probability of alloimmunization (Jha R, 2014). 
2.8.2. Allogeneic Hematopoietic Stem Cell Transplantation: 
The most important challenge in allogeneic stem cell transplantation therapy is the 
availability of human leukocyte antigen (HLA) compatible donors and the prevention of 
the graft versus host reaction (GVHR). The main purpose of the therapy is the replacement 
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of the affected hematopoietic stem cells with normal hematopoietic stem cells from a 
compatible donor to produce normal erythrocytes. There are three sources of hematopoietic 
stem cells for allogeneic transplantation: bone marrow, peripheral blood and cord blood. 
There are advantages and disadvantages for each source. The advantages for peripheral 
blood stem cell transplantation include easy donation, the harvesting of high doses of stem 
cells and faster hematological recovery, while the disadvantages include the higher 
probability of acute and chronic GVHD than with other stem cells sources (Appelbaum, 
Forman, Negrin, & Antin, 2015). 
The first allogeneic hematopoietic stem cell transplantation therapy was done in 1981 in 
Seattle, USA for a 14-month-old thalassemia major patient who had been transfused with 
250 mL of packed RBCs. This patient received compatible allogeneic hematopoietic stem 
cells for transplantation from his HLA-identical sister. The treatment was completely 
successful (Thomas et al., 1982). 
In the same period, in 1984, another hematopoietic stem cell transplantation therapy was 
undertaken in Pesaro in Italy for a 14-year-old thalassemia patient who had received 150 
mL packed RBC transfusions (Lucarelli et al., 1984). This patient received compatible 
allogeneic hematopoietic stem cells for transplantation from his HLA-identical brother. 
This patient rejected the graft and was the first of an extensive series of transplants for 
thalassemia (Appelbaum, Forman, Negrin, & Antin, 2015).  
2.8.3. Gene Therapy: 
Because β thalassemia is one of several single gene defect diseases worldwide, gene 
therapy could be used to express the normal β globin gene. This type of therapy depends 
on the autologous transfer of genetically modified hematopoietic stem cells. Many efforts 
have been made but with very limited success so far. The first successful trial was reported 
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in 2007 and the result was published after 33 months post-gene transfer (Cavazzana-Calvo 
et al., 2010). The trial was done in an adult patient with severe βE/β0-thalassaemia who was 
dependent on monthly transfusions and received hematopoietic stem cell lentiviral β globin 
gene therapy. After 21 months, 100% of hemoglobin A came from the modified cells and 
the patient was transfusion free. The patient subsequently experienced a good quality of 
life with a stable hemoglobin level of between 9 and 10 g/dl, and was transfusion-free and 
cancer-free for up to 7 years (Nienhuis, 2013). For this type of therapy there are still more 
trials needed (Bank, Dorazio, & Leboulch, 2005(. 
 
2.9. Related study 
There is a variation in the results according to the studies of the frequency of 
alloimmunization among transfusion-dependent thalassemia patients. However, there is no 
data available for the frequency among transfusion-dependent thalassemia patients in the 
State of Palestine. 
Previous studies have shown very high frequencies of alloimmunization among 
transfusion-dependent thalassemia patients ranging from 22% to 42%. The highest 
frequency of alloimmunization of 42.5% was presented in the province of Alexandria in 
Egypt which was reported by Obaid et al. in 2015. In a study by Wang et al. in Taiwan in 
2006, 37% of thalassemia major patients were found to carry alloantibodies.  
In another study by Ameen et al. in 2003 among transfusion dependent Arab thalassemia 
patients in Kuwait, the frequency of alloimmunization was 30%. Hussein et al. reported in 
a study done in Egypt in which 22.8% of the transfusion-dependent thalassemia patients 
have at least one alloantibody. In Greece, a frequency of alloimmunization of 22.6% was 
reported by Spanos et al. in 1990 (Ameen et al., 2003; Hussein, Desooky, Rihan, & Kamal, 
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2014; Obaid, Abo El-Nazar, Ghanem, El-Hadidi, & Mersal, 2015; TH Spanos et al., 1990; 
Wang et al., 2006).  
There are other studies reporting a low frequency of alloimmunization among transfusion-
dependent thalassemia patients. Pahuja et al. reported the frequency of alloimmunization 
among Indian origin thalassemia patients to be 3.8% (Pahuja, Pujani, Gupta, Chandra, & 
Jain, 2010).  
Seferi et al. reported that 11.8% of transfusion dependent Albanian thalassemia patients 
were alloimmunized, 10.1% of patients were already alloimmunized before the study and 
only 1.7% of patients were alloimmunized after applying a strict Rh and Kell matching 
policy (Seferi et al., 2015). In Egypt, different studies were done to identify the frequency 
of alloimmunization among transfusion-dependent thalassemia patients in different regions 
(Abdelrazik et al., 2016; el-Danasoury, Eissa, Abdo, & Elalfy, 2012; Hussein et al., 2014; 
Obaid et al., 2015). Abdelrazik et al. and Obaid et al. reported the frequency of 
alloimmunization among transfusion-dependent thalassemia patients in Fayoum province 
and Alexandria provinces respectively to be 8% and 42.5% (Abdelrazik et al., 2016; Obaid 
et al., 2015). 
Several studies have also been carried out in Iran. Davari et al., Amin et al., and Karimi et 
al. performed studies in the north-west, south-east and southern regions of Iran and 
reported that 16.3%, 17.9% and 5.3% of the transfusion-dependent thalassemia patients 
had been alloimmunized respectively. A descriptive study was also undertaken in Iran by 
Azarkeivan et al. in thalassemia centres (two were paediatric centres and two were adult 
centres) to identify the frequency of alloimmunization which was 7.7% of paediatric and 
14.4% of adult had alloantibodies (Amin, 2013; Azarkeivan et al., 2011; Davari & 
Soltanpour, 2016; Karimi, Nikrooz, Kashef, Jamalian, & Davatolhagh, 2007). 
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In 1985, Sirchia et al. reported that 5.2% of Italian transfusion-dependent thalassemia 
patients had been alloimmunized (Sirchia et al., 1985). Guirat-Dhouib et al. reported that 
7.7% of Tunisian transfusion-dependent thalassemia patients had at least one alloantibody 
(Guirat-Dhouib et al., 2011). Abdel Gader et al. reported that 22.06% of multi-transfused 
patients had been alloimmunized in Saudi Arabia (Gader, Al Ghumlas, & Al-Momen, 
2008). In india, in the Jammu region, Dogra et al. reported that 8.5% of transfusion-
dependent thalassemia child patients had been alloimmunized (Dogra, Sidhu, Kapoor, & 
Kumar, 2015). Haslina et al. reported that 8.6% of Malay transfusion-dependent 
thalassemia patients had alloantibodies (Haslina, Ariffin, Hayati, & Rosline, 2006). In 
Pakistan, Zaidi et al. reported that 8.6% of thalassemia transfusion-dependent patients had 
been alloimmunized (Zaidi et al., 2015). 
In the previous mentioned studies, several independent factors were studied including 
gender, status of spleen, number of transfusions, blood group (ABO/Rh-D) and age of 
starting transfusion therapy. The most important factor however was found to be the 
heterogeneity between the erythrocyte antigens of the donor and recipient. 
Splenectomy was reported as a risk factor for alloimmunization in several studies. Singer 
and Hussein suggest that Splenectomy is a risk factor for alloimmunization, that stimulate 
the immune system to produce alloantibodies due to predominantly abnormal RBC 
deformability (Singer et al., 2000, Hussein et al., 2014). While other studies showed that 
there is no association between alloimmunization and splenectomy (Al-Mousawi, Al-
Allawi, & Alnaqshabandi, 2015; Karimi, Nikrooz, Kashef, Jamalian, & Davatolhagh, 
2007; Pahuja, Pujani, Gupta, Chandra, & Jain, 2010; Sirchia et al., 1985). 
Furthermore, Singer and Al-Mousawi suggested that alloimmunization could be affected 
by a patient’s age at starting transfusion and that transfusion at an early age (less than 1-3 
   27 
 
years old) may offer some immune tolerance and protection against alloimmunization in 
transfusion-dependent thalassemia patients (Al-Mousawi, Al-Allawi, & Alnaqshabandi, 
2015; Singer et al., 2000). Other studies, reported that there is no significant association 
between alloimmunization and age of starting transfusion (Amin, 2013; Karimi, Nikrooz, 
Kashef, Jamalian, & Davatolhagh, 2007). 
Singer and Al-Mousawi suggested that there is no association between alloimmunization 
and the number of transfused units, though Karimi et al., Dogra et al. and Hussein et al. all 
suggested that there is significant correlation with the number of blood units. 
Female gender has been known as a risk factor for alloimmunization (Bauer et al., 2007). 
Moreover, Dogra et al. reported no significant association between alloimmunization and 
gender (Dogra et al., 2015). In fact, males had a higher alloimmunization rate in Hussein’s 
study (Hussein et al., 2014). 
Al-Mousawi et al. reported that there is significant association between alloimmunization 
and the absence of the Rh-D antigen (Al-Mousawi, Al-Allawi, & Alnaqshabandi, 2015). 
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Chapter Three 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ  
3. Materials and Methods 
 
3.1.Study design  
A cross-sectional study was done by convenient sampling from the transfusion-dependent 
thalassemia patient population in the middle and southern regions of the West Bank. This 
was done at the transfusion centres in the Palestinian Central Blood Bank in Ramallah, 
Jericho Hospital in Jericho and Hebron Hospital (Alia) in Hebron. 
Depending on recently updated data from Thalassemia Patients Friends Palestinian 
Society, in the West Bank there are 500 transfusion-dependent thalassemia patients, with 
153 patients (30.6%) in the investigated regions of the West Bank receiving blood 
transfusion in the centres mentioned. 
The study in the northern region of the West Bank was done in the first phase of our study 
in June 2016. The frequency of alloimmunization among transfusion-dependent 
thalassemia patients in northern region of the West Bank was 14% anti-D followed by anti-
K were the most frequent alloantibodies. 
  
3.2.Study Population and Sample Size 
Transfusion-dependent thalassemia patients in the middle and southern regions of the West 
Bank who met the inclusion criteria were the study population. 
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The sample size was calculated using the Raosoft® sample size calculator 
(http://www.raosoft.com/samplesize.html). The Raosoft® software indicated that the study 
had a 5% accepted margin of error, a 95% confidence level, and a 17% response 
distribution with the sample size being 101 transfusion-dependent thalassemia patients 
(male, n=52; female, n=49). Thirty-five patients (34.6%) were from the Palestinian Central 
Blood Bank, 5 patients (4.95%) were from the Jericho Hospital and 61 patients (60.4%) 
were from the Hebron Hospital. The distribution of the sample is illustrated in (Table 3.1).  
 
3.3.Inclusion and Exclusion Criteria 
Inclusion criteria: 
1. Transfusion-dependent thalassemia patients from south or middle of the West 
Bank. 
2. Any age 
3. Any gender 
4. Received at least ten transfusions. 
5. Last transfusion occur at least before 2 weeks 
Exclusion criteria: 
1. Transfusion-dependent thalassemia patients from north of the West Bank. 
2. Received less than ten transfusions. 
3.   Last transfusion occur in period less than 2 weeks.   
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3.4.Ethical Considerations 
The study was ethically approved by Institutional Review Board (IRB) at Al-Quds 
University Ref No: 5/REC/2017 (Appendix 3) and by the Palestinian Ministry of Health 
(PMOH). 
A brief explanation was given to the patients or their guardians. Then, the patients were 
asked to sign a consent form (Appendix 4) to approve their participation and the collection 
of blood samples from them. 
 
Table 3.1: Distribution of sample in terms of transfusion centres. 
 
Governorates 
 
Transfusion centre 
Population 
(%) 
 
Sample 
Size (%) 
Jericho Jericho Hospital 6 (3.9%) 5 (4.95%) 
Ramallah Central Blood 
Bank 
54 (35.3%) 35 (34.65%) 
Bethlehem Central Blood 
Bank 
1 (0.7%) --- 
Hebron Hebron Hospital 92 (60.1%) 61 (60.4) 
Total  153 (100%) 101 (100%) 
 
 
3.5. Data collection 
A small questionnaire (Appendix 5) was administrated –a face to face interview with the 
patients- to collect data such as age, gender, status of the spleen, age of starting transfusion 
and frequency of transfusion were obtained directly from the participants (or their legal 
guardians) or from the records of Palestinian Ministry of Health (PMOH). 
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3.6. Laboratory Investigations 
About ten ml of blood was collected from each participant: 5ml in an ethylene di-amine 
tetra-acetic acid (EDTA) tube and 5ml in a plain tube. Whole blood in EDTA tubes were 
stored in a refrigerator at 4⁰ C and serum from plain tubes was stored at -20⁰ C until the 
tests were performed in the hospital transfusion centres. After sample collection was 
completed, all samples were transferred to the An-Najah National University Hospital 
(NNUH) blood bank for testing.  
3.6.1. ABO and Rh-D Identification: 
To confirm the participants’ blood group from the PMOH data, blood grouping (ABO & 
Rh-D) was performed by two methods: reverse and forward blood grouping. Forward and 
reverse blood grouping were done by micro-tube gel methods (ID card-Diaclon 
ABO/D+Reverse grouping, Diamed ID, Switzerland). Commercial A and B cell 
suspensions (ID-Diacell ABO A1-B, Diamed ID, Switzerland) were used for reverse blood 
grouping. 
A cell suspensions (5%) were prepared from EDTA whole blood for each participant by 
adding 50µl of whole blood to 1mL of low ionic strength saline (LISS) (ID-Diluents II, 
Diamed ID, Switzerland). These suspensions were used for forward blood grouping. A 
volume of 12.5µl of the cell suspension was added to micro-tube 1 which contained anti-A, 
12.5µl of the cell suspension was added to micro-tube 2 which contained anti-B and 12.5µl 
of the cell suspension was added to micro-tube 3 which contained anti-D for forward blood 
grouping, and 12.5µl of the cell suspension was added to micro-tube 4 which is the control 
micro-tube.  
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For reverse blood grouping, 50µl of each participant’s serum were added to micro-tube 5 
and 6, 50µl of commercial A-cells were added to micro-tube 5, and 50µl of commercial B-
cells were added to micro-tube 6. 
After preparing the micro-tube gel cards for the participants, they were centrifuged for 10 
minutes. 
The result of forward and reverse blood grouping were done automatically using a 
WADiana® cc-702 compact analyser (Diagnostic Grifols, Spain) at the NNUH blood bank.  
As a control, three known blood group samples (A positive, B positive and O negative) 
were performed at each patch. 
3.6.2. Alloantibody Screening: 
The indirect Coombs test was done to detect the presence of alloantibodies by using micro-
tube gel cards with poly-specific antihuman globulin (anti-IgG) and an anti-C3d 
complement. In addition, three sets of commercial group O human RBCs that were typed 
for clinically significant antigens as well as rare antigens (ID-Diacell I-II-II, Diamed ID, 
Switzerland) were used in the indirect Coombs test for alloantibody screening. 
A volume of 50µl of ID-Diacell I was added to micro-tube 1, 50µl of ID-Diacell II was 
added to micro-tube 2, 50µl of ID-Diacell III was added to micro-tube 3, and 25µl of the 
participant’s serum was added to each micro-tube used. After preparing the micro-tube gel 
cards for the participants, these cards were incubated for 15 minutes at 37⁰ C in an ID-
incubator. Finally, they were centrifuged for 10 minutes. 
Two known samples were used as a control, Positive and negative samples were done at 
each patch.  
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Alloantibody screening and reading of the results were done automatically using a 
WADiana® cc-702 compact analyser (Diagnostic Grifols, Spain) at the NNUH blood bank.  
3.6.3. Alloantibody Identification: 
The indirect Coombs test was done to identify the alloantibodies which were detected in 
the antibody screening step. Micro-tube gel cards with poly-specific antihuman globulin 
(anti-IgG) and an anti-C3d complement were used, however 11 sets of commercial group 
O human RBCs that had been typed for clinically significant antigens as well as rare 
antigens (ID-DiaPanel, Diamed ID, Switzerland) were used in the indirect Coombs test for 
alloantibody identification. In two micro-tube gel cards, 50µl from each ID-DiaPanel set 
(1-11ID-DiaPanel) was added to separate micro-tubes (micro-tubes 1-6 in the first gel card 
and 7-11 in the second gel card). Then, 25µl of the participant’s serum was added to 
micro-tube 1-11. After preparing the micro-tube gel cards for the participants, they were 
incubated for 15 minutes at 37⁰ C in an ID-incubator. Finally, they were centrifuged for 10 
minutes. 
Alloantibody identification process and the reading of the results were done automatically 
using an WADiana® cc-702 compact analyser (Diagnostic Grifols, Spain) at the NNUH 
blood bank. A known sample, positive for anti-D was used at each patch as a control. 
 
3.7.Statistical Analysis 
Statistical analysis was performed by using the Statistical Package for the Social Science 
(SPSS) software (version 18.0, IBM, USA). It included descriptive statistics, frequency 
distribution, mean, and standard deviation calculations. Comparative studies were 
performed by using Chi-square test. Statistically significance was considered as a P value 
<0.05. 
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Chapter Four 
ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ 
4. Results 
 
4.1.Participants Characteristics 
In this research study, a total of 101 thalassemia patients were included. Eighty-eight 
participants (87.1%) were thalassemia major and 13 participants (12.9%) were thalassemia 
intermedia (Table 4.1). Forty-four participants (49%) were females and 52 participants 
(51%) were males, resulting in a female to male ratio of 0.94 (Figure 4.1).  
Table 4.1: Distribution of the thalassemia phynotypes of participants 
Diagnosis Number of participants Percentage 
Thalassemia Major 88 87.1% 
Thalassemia Intermedia 13 12.9% 
 
 
Figure 4.1: Distribution of gender of participants. 
Of the 101 participants, 61 were from Hebron (60.4%), 35 were from Ramallah (34.7%) 
and 5 were from Jericho (4.9%). 
The 101 patients were grouped to different group ages. Twenty-two of the 101 participants 
(21.8%) were less than 10 years old, 39 (38.6%) were between 10 and 20 years old, 27 
participants (26.7%) were between 20 and 30 years old and 13 (12.9%) were more than 30 
51% 49% 
Male Female
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years old. The age of the participants ranged from 3 to 53 years old, the mean was 19 
years, the median was 18 years and standard deviation was 9.8 years. 
In this study, 44 participants (43.6%) had A blood group, 29 (28.7%) had O blood group, 
18 (17.8%) had B blood group, and 10 (9.9%) had AB blood group (Table 4.2). 
Regarding to the D antigen in the Rh-system, 89 participants (88.1%) had positive Rh-D 
antigen and 12 participants (11.9%) had negative Rh-D antigen (Table 4.3). 
Table 4.2: Distribution of ABO among participants 
ABO 
 
Gender 
A B O AB 
 
Male 19 10 16 7 
Female 25 8 13 3 
Total 44 18 29 10 
 
 
 
Table 4.3: Distribution of Rh-D antigen among participants  
Rh-D 
 
Gender 
Positive Negative 
Male 49 3 
Female 40 9 
Total 89 12 
  
All the participants in this research received regular transfusions with post-storage 
leukoreduced packed red blood cells and the transfusion mean was 251, while the 
transfusions median was 208 with a range from 16 to 676. Finally, the standard deviation 
was 165. (Figure 4.2) summarize the transfusion number for the participants in this 
research. 
Forty-eight participants (47.5%) in this study were splenectomised (Figure 4.3). 
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Figure 4.2: Number of transfusions of participants. 
 
 
Figure 4.3: Distribution of Status of spleen. 
 
4.2.Antibody Screening 
In this research, 11 participants (10.9%) developed at least one alloantibody, ten of them 
were diagnosed with β-thalassemia major and one of them was diagnosed with β-
thalassemia intermidia. Among the participants with alloantibodies, the mean age was 22 
years with a ranging from 12 to 35 years, with eight participants being female and three 
being male. 
Eight of 11 alloimmunized participants were splenectomized. Among the eight 
splenectomized participants with alloantibodies, 5 were female and 3 were male. This 
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means that all of the alloimmunized male participants in this research were 
splenectomized. Appendix 6 summarizes the characteristics of alloimmunized participants. 
Among the alloimmunized participants, the mean number of transfusions was 388 with a 
range from 208 to 589 transfusions. 
Among the 11 participants with alloantibodies, 3 (27.3%) had A-Positive blood group, 2 
(18.2%) had A-Negative blood group, 2 (18.2%) had B-Positive blood group, one (9.1%) 
had O-Positive blood group, one (9.1 %) had O-Negative blood group and 2 (18.2%) had 
AB-Positive blood group. 
 
4.3.Antibody Identification 
Among 11 participants with alloantibodies, seven (63.6%) had developed single 
alloantibodies and four (36.4%) had developed more than one alloantibody (three of them 
had two alloantibodies and one had three alloantibodies). These 11 alloimmunized 
participants developed 6 different significant alloantibodies: three antibodies (50%) were 
against antigens belonging to the Rh-system (anti-E, anti-C and anti-D), two antibodies 
(33.3%) were against antigens belonging to the Kell-system (anti-K and antiKp
a
) and one 
antibody was against antigen belonging to the Kidd-system (anti-Jk
a
), (Table 4.4). 
Anti-E was found in 5 cases; in two cases as a single alloantibody (case-1 and case-3) and 
as multiple alloantibodies in three cases(caase-4, case-8 andcase-11). 
Anti-K was found in 3 cases, in one case as a single alloantibody (case-6) and as multiple 
alloantibodies (case-4 and case11). 
Moreover, anti-Jk
a
 was found in 3 cases, one as a single alloantibody (case-10) and two as 
multiple alloantibodies (case-8 and case-11). 
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Anti-D was found in 2 cases who are negative for D antigen, in one case as a single 
alloantibody (case-5). Anti-C was found in 2 cases, in one case as a single alloantibody 
(case-7). In case-9, anti-D and anti-C were present as multiple alloantibodies. 
 Anti-Kp
a
 was present in one case (case-2), (Appendix 6). 
Table 4.4: Alloantibodies detected among study participants 
Blood Group systems Abs Number Percentage 
 
Rh-system 
Anti-D 2 12.5% 
Anti-C 2 12.5% 
Anti-E 5 31.25% 
Kell-system Anti-K 3 18.75% 
Anti-Kp
a 
1 6.25% 
Kidd-system Anti-Jk
a 
3 18.75% 
Total  16 100% 
 
4.4. Association between Characteristics of Participants and Alloimmunization 
4.4.1. Governorates (Blood Transfusion Centres): 
This research study was done in three transfusion centres in the middle and southern areas 
of the West Bank. Most alloimmunized participants were from Hebron (10/11; 90.9%), just 
one alloimmunized participant was from Ramallah and no participants were detected from 
Jericho (Table 4.5). 
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There was no significant association between alloimmunization and transfusion centres (P-
value = 0.089 > 0.05). 
Table 4.5: Alloimmunized participants according to governorate with P-value 
 
Transfusion centre Number of 
alloimmunized 
patients 
Percentage out of 
101 
P-value 
Jericho 0/5  0 % 0.089 
Ramallah 1/35 0.99 % 
Hebron 10/61  9.9 % 
Total 11/101 10.89% 
 
 
4.4.2. Gender: 
Of the 11 alloimmunized participants, 8 were females (72.7%) and 3 were males (27.3%) 
(Figure 4.4). 
 
 
Figure 4.4: Distribution of alloimmunized participants according to gender.  
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This research study involved 49 female and 52 male participants, with 8 (16.3%) and 3 of 
these groups being alloimmunized (5.8%) respectively (Table 4.6). 
Table 4.6: Association between alloimmunization and gender  
 
 Alloimmunized Non-alloimmunized Total P-value 
Male 3 (5.8%) 49 (94.2%) 52 0.089 
Female 8 (16.3%) 41(83.7) 49 
Total 11 90 101 
There was no significant association between alloimmunization and gender (P-value = 
0.089 > 0.05). 
4.4.3. Age: 
The age of the participants was one of the variables in our study with a range from 3 to 53 
years old, a mean of 19 years, a median of 18 years and standard deviation of 9.8 years. 
All participants were categorized in different age groups as presented in (Table 4.7).  
There was no significant association found between alloimmunization and the age of 
participants (P-value = 0.248 > 0.05). 
Table 4.7: Association between alloimmunization and age 
 
Intervals Number of 
Participants 
Alloimmunized P-value 
≤ 10 years 22 (21.8%) 0 0.248 
>10-20 years 39 (38.6%) 4 
>20-30 years 27 (26.7%) 6 
>30-40 years 10 (9.9%) 1 
>40-50 years 2 (2%) 0 
>50-60 years 1 (1%) 0 
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4.4.4. Status of Spleen: 
Of the 101 participants in this research study, 48 were splenectomized (47.5%), of whom, 
8 were Alloimmunized (16.7%). (Figure 4.5). 
 
 
Figure 4.5: Alloimmunized participants according to status of spleen. 
 
There was no significant association between alloimmunization and status of spleen (P-
value = 0.076 > 0.05). 
4.4.5. Age of first blood transfusion: 
The population in this research study is thalassemia patients; as a result of having received 
transfusion therapy, most of the participants started blood transfusion before the age of 2 
years old. However, there were some exceptions, such as when the patient was diagnosed 
as thalassemia intermedia. Therefore, the starting transfusion age was classified into five 
categories as shown in (Figure 4.6). 
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No significant association was found between alloimmunization and age of starting 
transfusion (P-value = 0.802 > 0.05). 
 
 
Figure 4.6: Alloimmunized participants according to age of starting transfusion. 
 
4.4.6. Frequency of transfusion: 
The frequency of transfusion was classified into three periods as shown in (Table 4.8). 
Most participants received at least one unit of blood per month. 
Table 4.8: Association between alloimmunization and frequency of transfusion 
Frequency of 
Transfusion 
Number of 
Participants 
Alloimmunized P-value 
≥ 1 unit/month 80 (79.2%) 10 0.575 
< 1 unit/month 18 (17.8%) 1 
< 1 units/2 month 3 (2.9%) 0 
 
No significant association was found between alloimmunization and frequency of 
transfusion (P-value = 0.575 > 0.05). 
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4.4.7. Number of transfusion: 
In this research study, the number of transfusions range from 16 to 676, the mean was 251, 
the median was 208 and the standard deviation was 165. 
 
Table 4.9: Association between alloimmunization and number of transfusions 
Intervals Number of Participants 
(%) 
Alloimmunized P-value 
≤100 Transfusions 21 (20.8%) 0 0.069 
>100-200 Transfusions 24 (23.8%) 1 
>200-300 Transfusions 20 (19.8%) 3 
>300-400 Transfusions 18 (17.8%) 2 
>400-500 Transfusions 6 (5.9%) 1 
>500-600 Transfusions 11 (10.9%) 4 
>600 Transfusions 1 (1%) 0 
 
No significant association was found between alloimmunization and number of 
transfusions (P-value = 0.069 > 0.05) (Table 4.9). 
4.4.8. ABO/Rh-D blood group: 
In this research study, the ABO blood group system and Rh-D were independent variables. 
There was no significant association between alloimmunization and the ABO blood group 
(P-value = 0.193 > 0.05) (Table 4.10). Also, there was no significant association between 
alloimmunization and the status of the D antigen (P-value = 0.095 > 0.05) (Table 4.11). 
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Table 4.10: Association between alloimmunization and ABO blood group 
ABO Number of Participants (%) Alloimmunized P-value 
A 44 5 0.719 
B 18 2 
O 29 2 
AB 10 2 
 
 
Table 4.11: Association between alloimmunization and status of D antigen 
Rh-D Number of Participants (%) Alloimmunized P-value 
Positive 89 8 0.095 
Negative 12 3 
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Chapter Five 
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5. Discussion 
 
Thalassemia is a lifelong transfusion dependent disease. Continuous blood transfusion can 
cause alloimmunization against RBC antigens and complicate further treatment in these 
patients. The purpose of this study was to determine the frequency of RBC alloantibodies, 
the types of these antibodies and the factors that affect alloimmunization in these patients. 
In Palestine, thalassemia patients are treated by blood transfusion. However, blood 
transfusions are a double-edged sword; on one hand, they are lifesaving, while on the other 
hand, their complications are harmful. 
Thalassemia is reported to be common in the Mediterranean region, equatorial or near-
equatorial regions of the Arabian Peninsula, India and southern China (Jha R, 2014). 
This is the first study to have investigated the frequency of alloimmunization among 
transfusion-dependent thalassemia patients in Palestine. The prevalence of alloantibodies 
among transfusion-dependent thalassemia patients in this study was 10.9%. A similar 
alloimmunization rate was found by Seferi et al. in an Albanian population (11.8%) (Seferi 
et al., 2015). While rates were found in Pakistan to be 8.6% (Zaidi et al., 2015) and in 
Egypt to be 8% (Abdelrazik et al., 2016). 
A higher alloimmunization incidence was reported by Singer et al. in a study done in 
transfusion-dependent thalassemia patients of predominantly Asian descent (22%) (Singer 
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et al., 2000). This higher incidence was due to a heterogeneity between donor and 
recipients, 75% of alloimmunized patients were Asian and 85% of blood donors in local 
blood centres were white (Singer et al., 2000). Moreover, a higher incidence was reported 
by Wang et al. in Taiwan (37%), Ameen et al. in the Arab population in Kuwait (30%), 
Egyptian population by Hussein et al. (30%) and Spanos et al. in Greece (22.8%) (Ameen 
et al., 2003; Hussein et al., 2014; T. Spanos et al., 1990; Wang et al., 2006). The common 
cause of these higher incidence rates of alloimmunization could be due to heterogeneity 
between donors and blood recipients.   
Lower rates of alloimmunization were reported in Southern Iran (5.3 %) (Karimi et al., 
2007), Italy (5.2%) (Sirchia et al., 1985), Iraq (5.1%) (Al-Mousawi et al., 2015) and India 
(3.8%) (Pahuja et al., 2010). 
In this study, 56.3% of alloantibodies were against antigens from the Rh-system and 25% 
were against antigens from the Kell-system. The most common alloantibody was anti-E 
(31.25%) followed by anti-K (18.75%) and anti Jk
a
 (18.75%). This finding is similar to 
studies done in Egypt, India, Greece, Italy and Pakistan, which reported that alloantibodies 
which belong to the Rh-system were the most common followed by the Kell system 
(Hussein et al., 2014; Pahuja et al., 2010; Sirchia et al., 1985; T. Spanos et al., 1990; Zaidi 
et al., 2015). 
In a study done by Ameen et al., it was found that alloantibodies against antigens from the 
Kell-system are the most common alloantibodies followed by those against the Rh-system 
in alloimmunized transfusion-dependent Arab thalassemia patients in Kuwait, where anti-
K was the most common followed by anti-E (Ameen et al., 2003). Moreover, Karimi et al. 
and Davari in Iran reported that alloantibodies belonging to the Kell-system were the most 
   47 
 
common alloantibodies (Davari & Soltanpour, 2016; Karimi et al., 2007). A lower anti-K 
frequency of 0.53% was reported in Fayoum, Egypt. (Abdelrazik et al., 2016). 
The differences in alloimmunization rates are attributed to at least three main contributing 
factors as reported by Singer; the antigenicity difference between blood donors and 
recipients, the immune status of blood recipients and the immunomodulatory effect of the 
allogenic blood transfusions on the recipient’s immune system (Singer et al., 2000). 
The homogeneity of the Palestinian population could lead to an alloimmunization rate that 
is not as high as that found in other heterogeneous populations such as the Kuwaiti and 
Asian populations. This could also be due to the fact that all thalassemia patients in 
Palestine receiving post-storage leukoreduced blood. Hussein et al. suggested that 
leukoreduced blood reduces the alloimmunization rate (Hussein et al., 2014). Furthermore, 
matching phenotyping for the E antigen and K antigen as well as ABO/D antigens could 
lead to a reduction in the alloimmunization rate in Palestine. Singer proved that matching 
for the Rh-system and K antigens appears to be effective in preventing alloimmunization 
(Singer et al., 2000). 
We reported that there is no significant association between alloimmunization and 
Splenectomy. Furthermore, Sirchia et al. in Italy, Karimi et al. in Southern Iran, Pahuja et 
al. in India and Al-Mousawi et al. in Iraq reported that there is no association between 
alloimmunization and splenectomy (Al-Mousawi et al., 2015; Karimi et al., 2007; Pahuja 
et al., 2010; Sirchia et al., 1985). However, Singer and Hussein suggest that the absence of 
a spleen stimulates the immune system to produce alloantibodies due to predominantly 
abnormal RBC deformability (Hussein et al., 2014; Singer et al., 2000).  
Moreover, Singer and Al-Mousawi et al. suggested that alloimmunization could be 
affected by a patient’s age at first blood transfusion and that transfusion at an early age 
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(less than 1-3 years old) may offer some immune tolerance and protection against 
alloimmunization in transfusion-dependent thalassemia patients (Al-Mousawi et al., 2015; 
Hussein et al., 2014; Singer et al., 2000). However, Karimi and Amin et al. reported that 
there is no significant association between alloimmunization and age of starting transfusion 
and that there is no significant difference in the effect of alloimmunization between groups 
who received blood before and after 1 year old (Amin, 2013; Karimi et al., 2007). In 
addition, we reported that there is no significant association between alloimmunization and 
age of first blood transfusion. 
Moreover, we reported that there is no significant association between alloimmunization 
and number of transfusions, Also, Singer and Al-Mousawi et al. suggested that there is no 
association between alloimmunization and the number of transfused units, though Karimi 
et al., Dogra et al. and Hussein et al. all suggested that there is significant correlation with 
the number of blood units (Al-Mousawi et al., 2015; Dogra et al., 2015; Hussein et al., 
2014; Karimi et al., 2007; Singer et al., 2000). 
Female gender has been known as a risk factor for alloimmunization (Bauer et al., 2007); 
but we reported that there is no significant association between alloimmunization and 
gender. Moreover, Dogra et al. reported no significant association between 
alloimmunization and gender (Dogra et al., 2015). In fact, males had a higher 
alloimmunization rate in Hussein’s study (Hussein et al., 2014). 
We reported in the present study that there is no significant association between 
alloimmunization and ABO blood Group and Rh-D, though Al-Mousawi et al. reported 
that there is significant association between alloimmunization and the absence of the Rh-D 
antigen (Al-Mousawi et al., 2015). 
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6. Summary 
 
6.1.Conclusions 
Alloimmunization leads to an increase in blood transfusion complications and a 
reduction in the availability of compatible blood units. This serious complication 
is due to the presence of alloantibodies in chronically transfusion-dependent 
patients such as thalassemia patients. 
Antibodies against antigens belonging to the Rh-system and Kell-system are the 
most common alloantibodies in transfusion-dependent thalassemia patients in the 
middle and southern areas of the West Bank. Among the 16 significant 
alloantibodies identified in this study, anti-E are the most common alloantibody, 
followed by Anti-K, Anti-Jk
a
, Anti-C and Anti-D. 
We found no significant association between alloimmunization and several 
factors such as gender, splenectomy status, ABO blood group, status of Rh-D 
antigen, number of transfusions and age of starting transfusion. 
 
6.2.Limitations 
Clinical data were collected from a computerized system in the Palestinian Ministry of 
Health, but some data such as age of first blood transfusion, transfusion frequency and 
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number of transfused units were unavailable. Therefore, age of starting transfusion and 
transfusion frequency were estimated by patients or guardians and the number of 
transfused units was estimated by calculations from the age of starting transfusion and 
transfusion frequency. 
 
6.3.Recommendations 
In order to reduce alloimmunization in these patients, a policy to perform extended red cell 
phenotyping and issuing antigen-matched blood should be adopted. This antigen-matching 
should be carried out at least for K and E antigens in addition to ABO/D matching. 
Moreover, a policy to transfuse pre-storage leukoreduced blood units for transfusion-
dependent patients should be adopted. 
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Appendix 2: Blood Group Systems- Part 2 (ISBT, 2018) 
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 mroF tnesnoC :4 xidneppA
 
 جامعة القدس
 كلٌة الدراسات العلٌا
 برنامج العلوم الطبٌة المخبرٌة  
 مسار علم الدم
 الحمراء عند مرضى الثلاسٌمٌاتحدٌد الاجسام المضادة لانتٌجٌات خلاٌا الدم "
 "فً الضفة الغربٌة
 
 د. أدهم أبو طه     المشرفون:
 . خالد ٌونسد  
 
ولا ٌعد تكون الاجسام المضادة لانتٌجٌنات خلاٌا الدم الحرم من أحد اهم الأسباب المرتبطة بمضاعفات نقل الدم 
ومنتظم ومن أحد هذه الامراض التً ٌعتمد سٌما عندم المرضى الذٌن ٌرتكز علاجهم على نقل الدم بشكل دوري 
 علاجها فً فلسطٌن على نقل الدم بشكل دوري منتظم مرض الثلاسٌمٌا.
دراسة بحثٌة للتعرف  راءفاننً انا الطالب همام علً طالب فً كلٌة الدراسات العلٌا فً جامعة القدس بصدد اج
الذٌن ٌعتمد علاجهم على نقل  ة عند مرضى الثلاسٌمٌاعلى الاجسام المضادة لانتٌجنات خلاٌا الدم الحمراء المتكون
بهدف العمل على البحث عن الٌات للحد من تكون مثل هذه الاجسام المضادة بهدف  الدم بشكل دوري منتظم
 دها. والتقلٌل من مضاعفات نقل الدم المرتبطة بوج
وٌمكنك الاطلاع على نتائج الفحوصات كد لك بأن نتائج هذا الفحص سوف تستخدم لغرض البحث العلمً فقط ؤون
 الخاصة بك.
 ثم سٌتمهذا البحث ٌتضمن بعض الأسئلة عن طبٌعة حالتك المرضٌة وتارٌخك المرضً الشخصً والعائلً ومن 
 سحب عٌنة دم منك وفحصها لتحدٌد وجود او عدم وجود الأجسام المناعٌة المضادة لهذه الانتٌجٌنات.
فً الدراسة علٌنا أن نحٌطك علما أنه ٌمكنك الانسحاب من الدراسة فً اي  فً حال موافقتك على المشاركة
ستبقى سرٌة ولن ٌتم استخدامها الا  وأن معلوماتكمرحلة دون الحاجة لشرح الأسباب ودون التأثٌر على علاجك 
 العلمً.لأغراض البحث 
امراض نزف  أحدعانً من عملٌة سحب الدم قد تتضمن خطورة صغٌرة لحصول نزف زائد للدم فً حال كنت ت
 الممٌعات. أحدالدم او تأخذ 
 فً حال كان المرٌض قاصرا على ولً الأمر ان ٌوافق على مشاركته ومن ثم التأكد من رأي المرٌض نفسه.
 وشكرا لتعاونكم
 :/ولً أمرهتوقٌع /بصمة المشارك
 التارٌخ:
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Appendix 5: Sample Sheet 
Sample number  
Date of collection  
Transfusion centre  
Age  
Gender  
ABO & Rh  
Splenectomy  
Starting transfusion age  
Transfusion  
Frequency  
 
Antibody screening  
Antibody identification  
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Appendix 6: Characteristics of Alloimmunized Participants 
 
Case 
Number 
ABO Rh-D Gender Age 
(Years) 
Splenectomy Transfusions 
Number 
Alloantibodies 
Case-1 B Positive Male 17 Yes 287 Anti-E 
Case-2 B Positive Female 26 Yes 576 Anti-Kp
a 
Case-3 A Positive Female 14 NO 208 Anti-E 
Case-4 A Positive Female 12 NO 572 Anti-E & Anti-
K 
Case-5 O Negative Female 24 NO 564 Anti-D 
Case-6 O Positive Female 21 Yes 329 Anti-K 
Case-7 A Positive Male 21 Yes 120 Anti-C 
Case-8 AB Positive Male 35 Yes 589 Anti-E & Anti-
Jk
a 
Case-9 A Negative Female 22 Yes 372 Anti-C & Anti-
D 
Case-10 A Negative Female 18 Yes 294 Anti-Jk
a 
Case-11 AB Positive Female 28 Yes 485 Anti-E, Anti-K 
& Anti- Jk
a
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Appendix 7: Participants' demographic  
Variable Alloimmunized Non-alloimmunized Total P-value 
N (%) 11 90 101 --- 
Residency 0.089 
Ramallah 1 34 35 
Jericho 0 5 5 
Hebron 10 51 61 
Thalassemia Phenotypes 0.321 
Major 10 78 88 
Intermedia 1 12 13 
Gender 0.321 
Male 3 49 52 
Femal 8 41 49 
Blood Group 0.719 
A 5 39 44 
B 2 16 18 
O 2 27 29 
AB 2 8 10 
Status of Rh-D 0.095 
Positive 8 81 89 
Negative 3 9 12 
Splenectomy 0.095 
Yes 8 40 48 
No 3 50 53 
 
 
 
 16   
 
 الابيض عند مرضى فقر دم حوض البحر الغريبة الضدالكشف عن الاجسام المضادة لمولدات 
 المتوسط في الضفة الغربية
 اعداد: هوام عبد الرحون حسني علي
 طه اشراف: د. أدهن أبو
 هشرف ثاني: د. خالد يونس
 
 الممخص
 مقدمة:
و أن يقمل بشكل ممحوظ من مضاعفات ومخاطر مرض فقر دم حوض البحر أنإن نقل الدم من ش
. لكن مرضى الثلاسيميا بحاجة إلى نقل دم بشكل دوري ومستمر وىذا (الثلاسيميا)الأبيض المتوسط 
 ngieroFالغريبة ( الضد) ضد مولدات ydobitnaollAقد يؤدي إلى تكون أجسام مضادة (
 ) التي تحمميا خلايا الدم الحمراء في الدم المنقول لممرضى.snegitnA
ستفادة المريض من تقمل من درجة ا ةىذه الأجسام المضادة المتكونة قد تؤدي إلى مضاعفات خطير 
 د تصل المضاعفات إلى درجة قد تشكل خطورة عمى حياة المريض.قالدم المنقول و 
 الأهداف:
) لدى مرضى الثلاسيميا ydobitnaollAتيدف ىذه الدراسة الى تحديد نسبة تكون الاجسام المضادة (
في جنوب و وسط الضفة الغربية في فمسطين وتحديد انواعيا الاكثر انتشارا و تحديد العلاقة بين 
ة نقل دم و نوع الدم تكون مثل ىذه الاجسام المضادة و عوامل مختمفة كالجنس و العمر عند اول عممي
 و حالة استئصال الطحال.
 طريقة العمل:
وحتى حزيران من العام نفسو  2017تم عمل ىذه الدراسة في الفترة الممتدة من شير شباط من عام 
 الغربية. ووسط الضفةفي ثلاث مراكز لمرضى الثلاسيميا في جنوب 
كالعمر ومعدل فترات  والاكمينيكية لممرضىعينة حيث تم دراسة المعمومات السريرية  010تم جمع 
 الى نوع الدم. وتم الكشف بالإضافةالطحال  استئصالعممية نقل لمدم وحالة  اول والعمر عندنقل الدم 
 26   
 
تحديد  وايضا تمو في عينات المرضى المشاركين في الدراسة عن وجود الاجسام المضادة من عدم
 انواع ىذه الاجسام المضادة.
 النتائج
%) اغمبيم 1.10عينة مشاركة في الدراسة تحوي اجسام مضادة ( 010 أصلعينة من  00وجد ان 
%) تم 2.72يحممون اجسام مضادة ( الذيمن  8%)، وايضا كان 2.72;8كان من الاناث (
 استئصال الطحال لدييم سابقا.
 4، و المضادةنوع واحد من الاجسام  ونيحمم اكانو %) 6..6( 2من الذين يحممون اجسام مضادة، 
 %) يحممون نوعين من الاجسام المضادة او اكثر.4.6.(
  lleKواثنان يعودان لنظام  hRمنيم تعود لنظام  ثلاثةانواع مختمفة من الاجسام المضادة  6تم تحديد 
 .ddiKاما النوع الاخير فكان يعود لنظام 
 الخلاصة
اظيرت النتائج ارتفاعا في معدل الاجسام المضادة لدى مرضى الثلاسيميا الذين يعتمدون في علاجيم 
 .lleKو  hRعمى نقل الدم. وكانت الاجسام المضادة الاكثر شيوعا تمك التي نتتمي الى نظامي 
اوسع ومن اجل العمل عمى الحد من مثل ىذه الاجسام المضادة فاننا نوصي باتباع سياسات تطابق 
 .lleKو  hRفي نقل الدم ليؤلاء المرضى ولا سيما تطابق مولدات الاجسام المضادة من نظامي 
 
